Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937619 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 263
- Enrollment target
NCT06937619: Completed Phase 1 study, sponsored by AbbVie.
NCT06937619 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 263 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (338% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06937619, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 263 participants
- Enrollment target
Study Summary
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.
Primary Outcome
Maximum observed plasma concentration (Cmax) of Risankizumab
Interventions
- DRUG Risankizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2025-11-10 |
| Phase | Phase 1 |
What the finished NCT06937619 record still lists
NCT06937619 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (338% higher).
The record links to 0 conditions, and to 1 intervention - of which Risankizumab is the first listed.
NCT06937619 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06937619 about?
NCT06937619 is a clinical study titled "A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants". This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous (SC) administration with on-body Injector in Healthy Adult Participants.
What is the current status of trial NCT06937619?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 263 participants. The study started on 2025-04-21. Estimated completion is 2025-11-10.
What interventions are being tested in trial NCT06937619?
The interventions under investigation include: Risankizumab (DRUG).
Who is sponsoring clinical trial NCT06937619?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06937619's enrollment target sits among peer trials
263 158th of 2000 higher than 1,842 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI